pentobarbital will decrease the level or outcome of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Robust or moderate CYP3A inducers may possibly decrease cobimetinib systemic exposure by >80% and decrease its efficacy. Our miss